[{"orgOrder":0,"company":"SIWA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SIWA 318H","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIWA Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIWA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"SIWA Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by SIWA Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : SIWA recently announced the results of a study demonstrating that 318H binds to both COVID-19 and Influenza A, thus showing promise for 318H to become a broad-spectrum antiviral drug.

                          Product Name : SIWA 318H

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 16, 2020

                          Lead Product(s) : SIWA 318H

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank